Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

maveropepimut-S (MVP-S)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BioVaxys, EMD Serono

Drug class:

Survivin inhibitor

Related drugs:

BIRC5 expression	Diffuse Large B Cell Lymphoma	BIRC5 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria pembrolizumab + MVP-S Sensitive : C2	pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria pembrolizumab + MVP-S Sensitive : C2
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3